Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Supaglutide Phase 2 Study in Chinese Patients with Type 2 Diabetes
NCT04314622Phase 2Completed
- Sponsor
- Shanghai Innogen Pharmaceutical Technology Co., Ltd.
- Start
- Apr 2020
- Primary completion
- Oct 2020
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of efsubaglutide alfa in type 2 diabetes mellitus (T2DM), sponsored by Shanghai Innogen Pharmaceutical Technology Co., Ltd.. Started Apr 2020; status: completed.
02
Drugs
efsubaglutide alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04314622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04314622.